Plain-English translation of NCT04892303 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining two types of radiation therapy—radioactive iodine (I-131) and external beam radiation—can safely treat thyroid cancer that has come back or spread to other parts of your body. The study hypothesis is that using both treatments together allows doctors to deliver stronger, more effective radiation doses than either treatment could provide alone. This approach is designed for people whose cancer doesn't respond well enough to radioactive iodine therapy by itself.
Some patients with recurrent thyroid cancer don't benefit enough from radioactive iodine therapy alone because their cancer takes up too little of the radioactive material. This trial exists to see whether adding external beam radiation to the radioactive iodine treatment can improve outcomes and safely deliver higher doses of radiation to kill cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive radioactive iodine (I-131) followed by external beam radiation therapy targeting up to three tumors in your body. The study will carefully monitor you for safety during treatment and for 30 days after radiation ends, with an additional check-in at 6 months to see how well the treatment worked. Over the course of the 4-year study, researchers aim to enroll 48 patients total, with one new participant joining each month.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States